UPDATE: Credit Suisse Reiterates on Bristol-Myers Squibb on Divestiture of Stake in Diabetes Joint Venture

In a report published Friday, Credit Suisse analyst Vamil Divan reiterated an Outperform rating on Bristol-Myers Squibb (NYSE: BMY ), and raised the price target from $56.00 to $60.00. In the report, Credit Suisse noted, “Details of BMY's divestiture of its stake in its diabetes joint venture (JV) with AZN